•Membranous nephropathy secondary to very early-onset inflammatory bowel disease in a 3-year-old boy: case report
•Brominated Flame Retardants: UQCRC1 and NR3C2 as Potential Targets in IBD and CRC
•Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease
•An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients
•Gut microbiota alterations associated with anxiety and depression in inflammatory bowel disease: a systematic review of prospective cohorts and randomized trials
